Β-セクレターゼ1 (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Β-セクレターゼ1" in Japanese language version.

refsWebsite

Global rank Japanese rank

10nih.gov

4^th place

24^th place

9doi.org

2^nd place

6^th place

3harvard.edu

18^th place

107^th place

3alzforum.org

low place

2ensembl.org

1,626^th place

2,625^th place

2wikipedia.org

low place

2nature.com

234^th place

363^rd place

2astrazeneca.com

low place

1adam.com

low place

1web.archive.org

1^st place

1merck.com

6,464^th place

low place

1mercknewsroom.com

low place

1reuters.com

49^th place

67^th place

1elsevier.com

610^th place

915^th place

1karger.com

4,489^th place

low place

1worldcat.org

5^th place

19^th place

adam.com

pennstatehershey.adam.com

“Alzheimer's-fighting gene may inspire treatments”. (July 2012)

alzforum.org

“CoMentis BACE Inhibitor Debuts”. (April 2008)
“BACE Inhibitors Barrel Forward—Next Hurdles: Safety, Efficacy | ALZFORUM”. www.alzforum.org. 2019年5月3日閲覧。
“Lilly Halts Phase 2 Trial of BACE Inhibitor Due to Liver Toxicity | ALZFORUM”. www.alzforum.org. 2019年5月3日閲覧。

astrazeneca.com

“AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease” (16 Sep 2014). 8 Oct 2014閲覧。
“Update on Phase III Clinical Trials of lanabecestat” (12 June 2018). 20 June 2018閲覧。

doi.org

“Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE”. Science 286 (5440): 735–41. (Oct 1999). doi:10.1126/science.286.5440.735. PMID 10531052.
“Control of peripheral nerve myelination by the beta-secretase BACE1”. Science 314 (5799): 664–6. (Oct 2006). Bibcode: 2006Sci...314..664W. doi:10.1126/science.1132341. PMID 16990514.
“A mutation in APP protects against Alzheimer's disease and age-related cognitive decline”. Nature 488 (7409): 96–9. (Aug 2012). Bibcode: 2012Natur.488...96J. doi:10.1038/nature11283. PMID 22801501.
“Alzheimer therapeutics-what after the cholinesterase inhibitors?”. Age and Ageing 35 (4): 332–5. (Jul 2006). doi:10.1093/ageing/afl009. PMID 16644763.
“2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead”. Journal of Medicinal Chemistry 50 (18): 4261–4. (Sep 2007). doi:10.1021/jm0705408. PMID 17685503.
Willis, Brian; Martenyi, Ferenc; Dean, Robert; Lowe, Stephen; Nakano, Masako; Monk, Scott; Gonzales, Celedon; Mergott, Dustin et al. (2012-7). “Central BACE1 inhibition by LY2886721 produces opposing effects on APP processing as reflected by cerebrospinal fluid sAPPalpha and sAPPbeta” (英語). Alzheimer's & Dementia 8 (4): P582. doi:10.1016/j.jalz.2012.05.1584.
Pettersson, A.F.; Olsson, E.; Wahlund, L.-O. (2005). “Motor Function in Subjects with Mild Cognitive Impairment and Early Alzheimer’s Disease” (english). Dementia and Geriatric Cognitive Disorders 19 (5-6): 299–304. doi:10.1159/000084555. ISSN 1420-8008.
“BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics”. Human Molecular Genetics 10 (12): 1317–24. (Jun 2001). doi:10.1093/hmg/10.12.1317. PMID 11406613.
“Plasmepsin V licenses Plasmodium proteins for export into the host erythrocyte”. Nature 463 (7281): 632–6. (Feb 2010). Bibcode: 2010Natur.463..632R. doi:10.1038/nature08726. PMC 2826791. PMID 20130644.

elsevier.com

linkinghub.elsevier.com

Willis, Brian; Martenyi, Ferenc; Dean, Robert; Lowe, Stephen; Nakano, Masako; Monk, Scott; Gonzales, Celedon; Mergott, Dustin et al. (2012-7). “Central BACE1 inhibition by LY2886721 produces opposing effects on APP processing as reflected by cerebrospinal fluid sAPPalpha and sAPPbeta” (英語). Alzheimer's & Dementia 8 (4): P582. doi:10.1016/j.jalz.2012.05.1584.

ensembl.org

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000186318 - Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000032086 - Ensembl, May 2017

harvard.edu

ui.adsabs.harvard.edu

“Control of peripheral nerve myelination by the beta-secretase BACE1”. Science 314 (5799): 664–6. (Oct 2006). Bibcode: 2006Sci...314..664W. doi:10.1126/science.1132341. PMID 16990514.
“A mutation in APP protects against Alzheimer's disease and age-related cognitive decline”. Nature 488 (7409): 96–9. (Aug 2012). Bibcode: 2012Natur.488...96J. doi:10.1038/nature11283. PMID 22801501.
“Plasmepsin V licenses Plasmodium proteins for export into the host erythrocyte”. Nature 463 (7281): 632–6. (Feb 2010). Bibcode: 2010Natur.463..632R. doi:10.1038/nature08726. PMC 2826791. PMID 20130644.

karger.com

Pettersson, A.F.; Olsson, E.; Wahlund, L.-O. (2005). “Motor Function in Subjects with Mild Cognitive Impairment and Early Alzheimer’s Disease” (english). Dementia and Geriatric Cognitive Disorders 19 (5-6): 299–304. doi:10.1159/000084555. ISSN 1420-8008.

merck.com

“Merck Presents Results of a Phase I Clinical Trial Evaluating Investigational BACE inhibitor MK-8931 at American Academy of Neurology”. (April 2012). オリジナルの2012年7月28日時点におけるアーカイブ。

mercknewsroom.com

“Merck Initiates Phase II/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer's Disease”. (December 2012)

nature.com

nih.gov

pubmed.ncbi.nlm.nih.gov

“Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE”. Science 286 (5440): 735–41. (Oct 1999). doi:10.1126/science.286.5440.735. PMID 10531052.
“Control of peripheral nerve myelination by the beta-secretase BACE1”. Science 314 (5799): 664–6. (Oct 2006). Bibcode: 2006Sci...314..664W. doi:10.1126/science.1132341. PMID 16990514.
“A mutation in APP protects against Alzheimer's disease and age-related cognitive decline”. Nature 488 (7409): 96–9. (Aug 2012). Bibcode: 2012Natur.488...96J. doi:10.1038/nature11283. PMID 22801501.
“Alzheimer therapeutics-what after the cholinesterase inhibitors?”. Age and Ageing 35 (4): 332–5. (Jul 2006). doi:10.1093/ageing/afl009. PMID 16644763.
“2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead”. Journal of Medicinal Chemistry 50 (18): 4261–4. (Sep 2007). doi:10.1021/jm0705408. PMID 17685503.
“BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics”. Human Molecular Genetics 10 (12): 1317–24. (Jun 2001). doi:10.1093/hmg/10.12.1317. PMID 11406613.
“Plasmepsin V licenses Plasmodium proteins for export into the host erythrocyte”. Nature 463 (7281): 632–6. (Feb 2010). Bibcode: 2010Natur.463..632R. doi:10.1038/nature08726. PMC 2826791. PMID 20130644.

ncbi.nlm.nih.gov

reuters.com

“AstraZeneca and Lilly move Alzheimer's drug into big trial” (英語). Reuters. (2014年12月1日) 2019年5月3日閲覧。

web.archive.org

“Merck Presents Results of a Phase I Clinical Trial Evaluating Investigational BACE inhibitor MK-8931 at American Academy of Neurology”. (April 2012). オリジナルの2012年7月28日時点におけるアーカイブ。

wikipedia.org

en.wikipedia.org

GRCh38: Ensembl release 89: ENSG00000186318 - Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000032086 - Ensembl, May 2017

worldcat.org

search.worldcat.org

Pettersson, A.F.; Olsson, E.; Wahlund, L.-O. (2005). “Motor Function in Subjects with Mild Cognitive Impairment and Early Alzheimer’s Disease” (english). Dementia and Geriatric Cognitive Disorders 19 (5-6): 299–304. doi:10.1159/000084555. ISSN 1420-8008.